NRx Pharmaceuticals (NRXP) Competitors $3.17 -0.39 (-10.96%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$3.14 -0.02 (-0.79%) As of 10/10/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NRXP vs. AVIR, VOR, OGI, PRQR, HRTX, TRDA, CABA, ACRS, VTYX, and TNXPShould you be buying NRx Pharmaceuticals stock or one of its competitors? The main competitors of NRx Pharmaceuticals include Atea Pharmaceuticals (AVIR), Vor Biopharma (VOR), Organigram Global (OGI), ProQR Therapeutics (PRQR), Heron Therapeutics (HRTX), Entrada Therapeutics (TRDA), Cabaletta Bio (CABA), Aclaris Therapeutics (ACRS), Ventyx Biosciences (VTYX), and Tonix Pharmaceuticals (TNXP). These companies are all part of the "pharmaceutical products" industry. NRx Pharmaceuticals vs. Its Competitors Atea Pharmaceuticals Vor Biopharma Organigram Global ProQR Therapeutics Heron Therapeutics Entrada Therapeutics Cabaletta Bio Aclaris Therapeutics Ventyx Biosciences Tonix Pharmaceuticals Atea Pharmaceuticals (NASDAQ:AVIR) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability. Do analysts rate AVIR or NRXP? Atea Pharmaceuticals presently has a consensus target price of $6.00, suggesting a potential upside of 91.08%. NRx Pharmaceuticals has a consensus target price of $34.50, suggesting a potential upside of 988.33%. Given NRx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe NRx Pharmaceuticals is more favorable than Atea Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atea Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00NRx Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71 Which has better valuation & earnings, AVIR or NRXP? Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than NRx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtea PharmaceuticalsN/AN/A-$168.38M-$1.61-1.95NRx PharmaceuticalsN/AN/A-$25.13M-$2.24-1.42 Which has more volatility and risk, AVIR or NRXP? Atea Pharmaceuticals has a beta of 0.22, meaning that its stock price is 78% less volatile than the S&P 500. Comparatively, NRx Pharmaceuticals has a beta of 1.74, meaning that its stock price is 74% more volatile than the S&P 500. Do institutionals & insiders believe in AVIR or NRXP? 86.7% of Atea Pharmaceuticals shares are held by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are held by institutional investors. 18.1% of Atea Pharmaceuticals shares are held by company insiders. Comparatively, 19.0% of NRx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media favor AVIR or NRXP? In the previous week, NRx Pharmaceuticals had 4 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 9 mentions for NRx Pharmaceuticals and 5 mentions for Atea Pharmaceuticals. NRx Pharmaceuticals' average media sentiment score of 0.72 beat Atea Pharmaceuticals' score of 0.71 indicating that NRx Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atea Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NRx Pharmaceuticals 2 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Is AVIR or NRXP more profitable? NRx Pharmaceuticals' return on equity of 0.00% beat Atea Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Atea PharmaceuticalsN/A -32.55% -30.47% NRx Pharmaceuticals N/A N/A -550.94% SummaryNRx Pharmaceuticals beats Atea Pharmaceuticals on 11 of the 14 factors compared between the two stocks. Get NRx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NRXP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NRXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NRXP vs. The Competition Export to ExcelMetricNRx PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$70.52M$2.65B$6.10B$10.63BDividend YieldN/A56.72%5.67%4.71%P/E Ratio-1.4222.9185.2726.57Price / SalesN/A745.20612.78132.63Price / CashN/A179.8938.5062.09Price / Book-2.145.3712.726.53Net Income-$25.13M$32.78M$3.30B$275.96M7 Day Performance-3.06%2.34%0.94%-0.73%1 Month Performance10.07%8.04%6.34%3.71%1 Year Performance131.39%-1.76%80.41%37.30% NRx Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NRXPNRx Pharmaceuticals3.0968 of 5 stars$3.17-11.0%$34.50+988.3%+130.5%$70.52MN/A-1.422Analyst ForecastAVIRAtea Pharmaceuticals1.8146 of 5 stars$2.92-0.3%$6.00+105.5%-6.0%$232.52MN/A-1.8170News CoveragePositive NewsAnalyst ForecastVORVor Biopharma3.1018 of 5 stars$39.89+18.6%N/AN/A$230.43MN/A-0.15140News CoverageAnalyst ForecastInsider TradeGap DownHigh Trading VolumeOGIOrganigram Global1.1536 of 5 stars$1.97+16.6%N/A+15.1%$227.04M$117.47M39.41860News CoverageAnalyst ForecastHigh Trading VolumePRQRProQR Therapeutics1.9407 of 5 stars$2.19+3.8%$8.00+265.3%+28.2%$222M$20.46M-4.76180News CoverageAnalyst ForecastHRTXHeron Therapeutics3.9599 of 5 stars$1.27+5.0%$4.50+254.3%-29.7%$221.81M$149.69M-63.50300News CoveragePositive NewsAnalyst UpgradeTRDAEntrada Therapeutics2.6687 of 5 stars$5.84+0.7%$25.67+339.5%-61.5%$220.62M$79.48M-3.28110News CoverageAnalyst ForecastCABACabaletta Bio2.9551 of 5 stars$2.38+0.8%$14.50+509.2%-41.3%$215.86MN/A-0.8850Trending NewsAnalyst ForecastGap UpACRSAclaris Therapeutics2.4957 of 5 stars$1.92-3.5%$8.71+353.9%+61.2%$215.58M$18.72M-1.40100VTYXVentyx Biosciences2.062 of 5 stars$3.03+1.7%$7.50+147.5%+73.7%$212.50MN/A-1.8030News CoverageAnalyst ForecastTNXPTonix Pharmaceuticals2.8068 of 5 stars$24.76+2.3%$70.00+182.7%+50.9%$212.22M$9.83M-0.6350Analyst Forecast Related Companies and Tools Related Companies Atea Pharmaceuticals Alternatives Vor Biopharma Alternatives Organigram Global Alternatives ProQR Therapeutics Alternatives Heron Therapeutics Alternatives Entrada Therapeutics Alternatives Cabaletta Bio Alternatives Aclaris Therapeutics Alternatives Ventyx Biosciences Alternatives Tonix Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NRXP) was last updated on 10/11/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NRx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NRx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
